SYK Inhibitors
1 drugsAbout SYK
Spleen tyrosine kinase (SYK) is an intracellular non-receptor tyrosine kinase crucial for signal transduction in hematopoietic cells. It plays a key role in immune cell development, activation, and function through various signaling pathways.
SYK's involvement in critical cellular processes makes it a compelling target for drug development, particularly in immune-related disorders. Currently, there is no genetic evidence directly linking SYK to specific diseases.
SYK is targeted by one FDA-approved drug, TAVALISSE, a small molecule used in 'other' therapeutic areas. Rigel Pharmaceuticals is the sole company with an approved SYK-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Lung Transplantation with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top SYK Drugs
Rigel Pharmaceuticals is the only company with an approved drug targeting SYK.
Low competition suggests an opportunity for other companies to enter the SYK inhibitor market.
SYK Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SYK, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for antibody or protein-based therapeutics.
SYK Clinical Trials 54 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 17 | 0 | 4 | 100% |
| Phase 2 | 23 | 11 | 11 | 1 | 50% |
| Phase 3 | 10 | 8 | 1 | 0 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SYK Drug Approval Timeline (2018 - 2018)
The first and only drug, TAVALISSE, was approved in 2018.
Recent entry suggests potential for further drug development, but also possible market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 35 clinical trials targeting SYK.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities